<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Publications - CRLM LT Clinical Resource</title>
    <link rel="stylesheet" href="../css/style.css?v=1733591400000">
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="container">
            <div class="nav-container">
                <div class="logo">CRLM LT Resource</div>
                <button class="hamburger" id="hamburger">
                    <span></span>
                    <span></span>
                    <span></span>
                </button>
                <ul class="nav-menu" id="navMenu">
                    <li><a href="../index.html">Home</a></li>
                    <li><a href="overview.html">Overview</a></li>
                    <li><a href="selection-criteria.html">Selection Criteria</a></li>
                    <li><a href="outcomes.html">Clinical Outcomes</a></li>
                    <li><a href="tools.html">Tools</a></li>
                    <li><a href="faq.html">FAQ</a></li>
                    <li><a href="glossary.html">Glossary</a></li>
                    <li><a href="case-studies.html">Cases</a></li>
                    <li><a href="bridging-therapy.html">Bridging Therapy</a></li>
                    <li><a href="lt-vs-resection.html">LT vs Resection</a></li>
                    <li><a href="survival-curves.html">Survival Curves</a></li>
                    <li><a href="pdf-resources.html">PDF Resources</a></li>
                    <li><a href="patient-flowchart.html">Patient Flowchart</a></li>
                    <li><a href="resources.html">Resources</a></li>
                    <li><a href="publications.html" class="active">Publications</a></li>
                    <li><a href="about-research-group.html">About Research Group</a></li>
                </ul>
            </div>
        </div>
    </nav>

    <!-- Main Content -->
    <main class="main-content">
        <!-- Page Header -->
        <section class="page-header">
            <div class="container">
                <h1>Research Group Publications</h1>
                <p class="subtitle">Key publications from the Transplant Oncology Research Group, Oslo University Hospital</p>
            </div>
        </section>

        <!-- Publications Section -->
        <section class="section">
            <div class="container">
                <h2>Featured Publications on LT for CRLM</h2>
                <p>The Transplant Oncology Research Group at Oslo University Hospital has published extensively on liver transplantation for colorectal liver metastases. Below are key publications that have shaped the evidence base for this emerging treatment modality.</p>

                <!-- 2024 Publications -->
                <div class="publication-year">
                    <h3>2024</h3>
                    
                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial</h4>
                            <p class="publication-authors"><strong>Adam R, Dueland S, Smedman TM, et al.</strong></p>
                            <p class="publication-journal">The Lancet, 2024</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> The first randomized controlled trial demonstrating that liver transplantation plus chemotherapy significantly improves 5-year overall survival (56.6% vs 12.6%) compared to chemotherapy alone in patients with permanently unresectable CRLM.</p>
                            <p><strong>Key Finding:</strong> Hazard ratio 0.37 (95% CI 0.22-0.62), representing a 4.5-fold survival benefit for LT.</p>
                        </div>
                    </div>

                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Resection Details, Donor Segment Volume, and Adjuvant Chemotherapy After Living Donor Liver Transplantation for Colorectal Liver Metastases</h4>
                            <p class="publication-authors"><strong>Dueland S, Grut H, Solheim JM, et al.</strong></p>
                            <p class="publication-journal">Transplantation, 2024</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> Comprehensive analysis of living donor liver transplantation (LDLT) outcomes for CRLM, addressing technical aspects and adjuvant therapy.</p>
                            <p><strong>Key Finding:</strong> LDLT expands access to transplantation and offers comparable or superior outcomes compared to deceased donor LT.</p>
                        </div>
                    </div>
                </div>

                <!-- 2023 Publications -->
                <div class="publication-year">
                    <h3>2023</h3>
                    
                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial</h4>
                            <p class="publication-authors"><strong>Dueland S, Smedman TM, Grut H, et al.</strong></p>
                            <p class="publication-journal">JAMA Surgery, 2023</p>
                            <p class="publication-citation">Cited by 82</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> Landmark study establishing the Oslo Score and demonstrating long-term survival outcomes in carefully selected CRLM patients undergoing LT.</p>
                            <p><strong>Key Findings:</strong></p>
                            <ul>
                                <li>10-year overall survival: 88.9% (Oslo Score 0-1) vs 11.7% (Oslo Score 3-4)</li>
                                <li>Oslo Score is a validated prognostic tool for patient selection</li>
                                <li>Molecular profiling (RAS/TP53 status) predicts outcomes</li>
                            </ul>
                        </div>
                    </div>

                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Transplantation for Nonresectable Colorectal Liver Metastases: Long-Term Follow-Up of the First Prospective Pilot Study</h4>
                            <p class="publication-authors"><strong>Solheim JM, Dueland S, Line PD, et al.</strong></p>
                            <p class="publication-journal">Annals of Surgery, 2023</p>
                            <p class="publication-citation">Cited by 65</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> Long-term follow-up of the pioneering SECA-I trial, confirming the durability of LT outcomes for CRLM.</p>
                            <p><strong>Key Finding:</strong> LT for carefully selected nrCRLM can provide long-term survival and potentially cure for selected patients, with OS excellent compared to oncological treatment alone.</p>
                        </div>
                    </div>

                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Where Are We Now With Liver Transplant for Colorectal Metastasis?</h4>
                            <p class="publication-authors"><strong>Ch√°vez-Villa C, Dueland S, Smedman TM, et al.</strong></p>
                            <p class="publication-journal">Current Transplantation Reports, 2023</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> Comprehensive review of the current state of LT for CRLM, summarizing evidence and clinical practice.</p>
                            <p><strong>Key Focus:</strong> Patient selection criteria, prognostic factors, and outcomes in the modern era.</p>
                        </div>
                    </div>
                </div>

                <!-- 2022 Publications -->
                <div class="publication-year">
                    <h3>2022</h3>
                    
                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Survival After Liver Resection and Liver Transplantation for Colorectal Liver Metastases: A Comparative Analysis Stratified by Metabolic Tumor Volume Assessed by PET</h4>
                            <p class="publication-authors"><strong>Grut H, Line PD, Labori KJ, Schulz A, Dueland S</strong></p>
                            <p class="publication-journal">HPB (Oxford), 2022</p>
                            <p class="publication-citation">Cited by 8</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> Comparative effectiveness study demonstrating that LT provides superior outcomes compared to resection in patients with high metabolic tumor volume.</p>
                            <p><strong>Key Finding:</strong> PET-MTV is a valuable prognostic factor for stratifying patients and selecting optimal treatment modality.</p>
                        </div>
                    </div>
                </div>

                <!-- 2021 Publications -->
                <div class="publication-year">
                    <h3>2021</h3>
                    
                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Liver Transplantation for Non-Resectable Colorectal Liver Metastases: The International Hepato-Pancreato-Biliary Association Consensus Guidelines</h4>
                            <p class="publication-authors"><strong>Bonney GK, Dueland S, Smedman TM, et al.</strong></p>
                            <p class="publication-journal">The Lancet Gastroenterology & Hepatology, 2021</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> International consensus guidelines establishing evidence-based recommendations for LT in CRLM.</p>
                            <p><strong>Key Contributions:</strong> Selection criteria, patient evaluation protocols, and best practices for multidisciplinary assessment.</p>
                        </div>
                    </div>

                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Survival Outcomes After Portal Vein Embolization and Liver Resection Compared With Liver Transplant for Patients With Extensive Colorectal Cancer Liver Metastases</h4>
                            <p class="publication-authors"><strong>Dueland S, Grut H, Smedman TM, et al.</strong></p>
                            <p class="publication-journal">JAMA Surgery, 2021</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> Comparative effectiveness study showing superior outcomes with LT versus PVE + resection for extensive CRLM.</p>
                            <p><strong>Key Finding:</strong> 5-year OS 33.4% (LT) vs 6.7% (PVE + resection) in high tumor load patients.</p>
                        </div>
                    </div>

                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Liver Transplantation for Unresectable Colorectal Liver Metastases in Patients and Donors With Extended Criteria (SECA-II Arm D Study)</h4>
                            <p class="publication-authors"><strong>Smedman TM, Dueland S, Line PD, et al.</strong></p>
                            <p class="publication-journal">BJSOpen, 2020</p>
                            <p class="publication-citation">Cited by 92</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> Landmark SECA-II trial demonstrating feasibility and safety of LT using extended criteria for both patients and donors.</p>
                            <p><strong>Key Finding:</strong> Extended criteria can expand access to LT while maintaining acceptable outcomes in carefully selected patients.</p>
                        </div>
                    </div>
                </div>

                <!-- 2020 and Earlier -->
                <div class="publication-year">
                    <h3>2020 and Earlier</h3>
                    
                    <div class="publication-item">
                        <div class="publication-header">
                            <h4>Liver Transplantation for Unresectable Colorectal Liver Metastases</h4>
                            <p class="publication-authors"><strong>Smedman TM, Hagness M, Dueland S, et al.</strong></p>
                            <p class="publication-journal">Annals of Surgery, 2019</p>
                            <p class="publication-citation">Cited by 92</p>
                        </div>
                        <div class="publication-content">
                            <p><strong>Significance:</strong> Pioneering work establishing the feasibility and efficacy of LT for CRLM in the modern era.</p>
                            <p><strong>Key Finding:</strong> LT provides excellent long-term survival outcomes in carefully selected patients with unresectable CRLM.</p>
                        </div>
                    </div>
                </div>

                <!-- Research Impact -->
                <div class="highlight-box research-impact">
                    <h3>Research Impact</h3>
                    <p>The Transplant Oncology Research Group's publications have been instrumental in:</p>
                    <ul>
                        <li>Establishing LT as a validated treatment option for unresectable CRLM</li>
                        <li>Developing evidence-based patient selection criteria (Oslo Score, FCRS, PET-MTV)</li>
                        <li>Demonstrating superior outcomes with LT compared to chemotherapy alone (TransMet trial)</li>
                        <li>Expanding access through living donor liver transplantation (LDLT)</li>
                        <li>Contributing to international consensus guidelines (IHPBA)</li>
                        <li>Advancing understanding of tumor biology and prognostic factors</li>
                    </ul>
                </div>

                <!-- Access to Publications -->
                <div class="section-box">
                    <h3>Accessing Full Publications</h3>
                    <p>Most publications are available through:</p>
                    <ul>
                        <li><strong>PubMed Central:</strong> Free full-text access to many articles</li>
                        <li><strong>Journal Websites:</strong> Direct access through publisher sites</li>
                        <li><strong>ResearchGate:</strong> Authors often share preprints and full texts</li>
                        <li><strong>Oslo University Hospital:</strong> Institutional access to subscription journals</li>
                    </ul>
                    <p>For inquiries about specific publications, contact the Transplant Oncology Research Group directly.</p>
                </div>
            </div>
        </section>
    </main>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>&copy; 2025 CRLM LT Clinical Resource. Evidence-based information for transplant teams.</p>
            <p class="author"><strong>Created by:</strong> Tor Magnus Smedman, MD PhD | Transplant Oncology Research Group, Oslo University Hospital</p>
            <p class="disclaimer">This resource is for educational purposes. Clinical decisions should be made in consultation with a multidisciplinary team.</p>
        </div>
    </footer>

    <script src="../js/main.js?v=1733591400000"></script>
</body>
</html>
